Fermer le menu


Member of Lyonbiopole


Synthelis is a service provider (CRO) for recombinant protein production using a proprietary cell-free expression system. Synthelis technology and know-how address difficult-to-express proteins with standard cell-based expression systems. The major proteins concerned are membrane proteins as  well as cytotoxic proteins. 

The Synthelis offering is divided up into the following areas:

- Expression feasibility phase

- Activity validation phase (using SPR, patch-clamp…)

- Optimization phase to improve activity levels or purity rates

- Scale-up of production (several milligrams / month)Synthelis is also developing new approaches for protein therapy and vaccine development based on membrane protein delivery by liposomal vectors.


Strategic application domain: Human Medicine

Application market: Infectious Diseases, Oncology

Type of activity: CRO - Tools - R&D platform, Therapeutics, Pharma or Biotech

Technologies: Antibodies - Protein - Peptide, Drug delivery device & Technologies

Created on jan. 3rd, 2011 - 9 employees



5 avenue du Grand Sablon 38700 La Tronche



Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.